Browse the evidence

Tirzepatide mitigates ischemic stroke damage by restoring Blood-Brain Barrier (BBB) integrity via Claudin-1 expression and reducing neuroinflammation.

This finding is currently limited to animal studies. While promising for stroke recovery, it does not yet translate to a standard human treatment protocol for acute stroke.

High-quality studies are needed to provide definitive answers regarding the safety and duration of preoperative drug cessation for GLP-1-RAs.

Clinicians should advocate for more research to establish clear guidelines for GLP-1-RAs in the perioperative context.

There are numerous research opportunities to explore the use of metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention.

Researchers should focus on investigating the cancer prevention potential of obesity treatments.

Long-term data on the efficacy and safety of Tirzepatide are still forthcoming.

Practitioners should remain cautious and await further data on long-term outcomes before fully endorsing TZP.

Pharmacovigilance is vital in real-world settings due to the absence of sufficiently long-term studies.

Clinicians should remain vigilant about the long-term effects of AOMs in practice.

The high pricing of semaglutide (₹17,000–26,000/month) threatens equitable access.

Practitioners should be aware of the cost barriers that may limit patient access to semaglutide.

Beta-amyrin acetate, a compound derived from the medicinal fungus Poria cocos, acts as a putative antagonist of the Neuropeptide Y1 receptor (Y1R) by binding to the orthosteric site with high affinity, potentially inhibiting feeding behavior associated with obesity.

Beta-amyrin acetate is a specific chemical compound found in the fungus Poria cocos. Current research is purely computational (computer simulations), predicting it might block a specific brain receptor (Y1R) involved in hunger. There is no human dosing protocol or clinical evidence yet; do not use this as a weight loss treatment based on this paper alone.

BMI categories are arbitrary classifications that do not accurately reflect health risks or body fat levels, and using them as a proxy for disease leads to misdiagnosis and stigma.

Do not rely on BMI alone to determine your health. It is an arbitrary cutoff that fails to account for muscle mass or individual health markers. Focus on how you feel, your fitness, and metabolic health markers rather than a number on a scale.

Bariatric surgery (RYGB, sleeve gastrectomy) does not result in clinically significant improvements in semen volume, sperm concentration, morphology, or DNA damage in men with obesity.

Do not expect bariatric surgery to improve your fertility. While it helps with weight, studies show it does not significantly improve sperm quality or DNA integrity. If fertility is a priority, lifestyle changes are a more reliable first step.

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

The LPAR1 antagonist EPGN2154, administered orally at 10 mg/kg, significantly reduces hepatic fibrosis and improves liver histology in preclinical NASH models, independent of body weight loss.

This research identifies a specific drug candidate (EPGN2154) that targets liver fibrosis directly through receptor antagonism, rather than just reducing body weight. While not yet available for humans, it highlights that treating NASH may require specific molecular interventions beyond just weight loss, particularly for fibrosis regression.

Combination therapy of the LPAR1 antagonist EPGN2154 and the GLP-1 agonist Semaglutide results in the maximum body weight loss and fat mass reduction in diet-induced obese mice, outperforming either drug alone.

Combining a GLP-1 agonist (like Semaglutide) with an LPAR1 antagonist (like EPGN2154) appears to maximize weight loss in preclinical models, potentially offering a synergistic effect for obesity management.

Self-administered overdose of Semaglutide (up to 8x the weekly dose) can cause multiorgan failure, including acute kidney injury, cholestatic liver dysfunction, and gastrointestinal bleeding, in patients with Type 2 Diabetes.

If you are using Semaglutide, never inject more than the prescribed weekly dose, even if you feel you need to 'catch up' or are experiencing side effects. The delivery pen allows you to inject multiple times, which can lead to life-threatening organ failure. If you feel dysphoric or suicidal, seek immediate help and do not attempt to self-medicate or overdose.

An intensive weight loss intervention combining total diet replacements (TDR), behavioral support, and weight loss medications (WLM) as needed achieves and maintains ≥20% weight loss in adults with obesity class I or II, significantly outperforming usual care.

To achieve significant weight loss (≥20%), you need a structured, long-term (2-year) program that combines strict initial calorie restriction (via meal replacements), regular coaching, and physical activity. If you don't lose enough weight in the first month, the program adds medication support. This is more intensive than typical 'eat less, move more' advice, which usually results in minimal weight loss.

Once-weekly subcutaneous semaglutide 2.4 mg produces clinically significant, sustained weight loss (mean -10.2% at 208 weeks) in adults with preexisting cardiovascular disease and obesity/overweight without diabetes, compared to placebo.

If you have heart disease and are overweight or obese (even without diabetes), once-weekly semaglutide 2.4 mg can help you lose about 10% of your body weight over 4 years, which is significantly more than placebo. This benefit is seen across different sexes, races, and BMI categories, though those with lower starting BMI might stop the medication more often due to side effects or lack of motivation. The key is that it works sustainably for cardiovascular health.

Semaglutide (2.4 mg/week) induces significant weight loss (mean -10.09% body weight) and improves cardiometabolic markers (BMI, waist circumference, blood pressure, CRP, lipids) in obese or overweight non-diabetic adults, with efficacy increasing with dose.

For non-diabetic adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) is a highly effective treatment for weight loss, averaging a 10% reduction in body weight. It also improves blood pressure, inflammation (CRP), and lipid profiles. While gastrointestinal side effects like nausea are common, they are typically transient. The treatment is dose-dependent, with higher doses yielding greater weight loss.

Long-term use of FDA/Health Canada-approved obesity pharmacotherapies (semaglutide, tirzepatide, liraglutide, naltrexone-bupropion, orlistat) combined with health behavior changes produces clinically meaningful weight loss and prevents weight regain upon discontinuation.

If you have obesity (BMI ≥ 30, or ≥ 27 with health issues), talk to your doctor about FDA/Health Canada-approved weight loss medications like semaglutide or tirzepatide. These work best when combined with diet and exercise changes. Crucially, these are long-term treatments; stopping them usually leads to regaining the weight, so view them as a permanent tool for managing your health, not a quick fix.

Tirzepatide (5-15 mg weekly) produces superior weight loss compared to semaglutide and placebo in adults with obesity, with dose-dependent efficacy.

Tirzepatide is a weekly injection that can lead to significant weight loss (up to ~21% in trials). It works by targeting two hormones (GIP and GLP-1). Side effects like nausea are common but often temporary. It is approved for adults with obesity or overweight with health issues.

A 12-week online intervention combining tailored protein intake counseling with progressive resistance training improves physical function, muscle strength, and health-related quality of life in older cancer survivors compared to general education and stretching.

If you are an older cancer survivor experiencing physical weakness, consider a program that combines specific dietary advice on protein intake with structured resistance exercises. This study protocol suggests that doing this online with professional guidance for 12 weeks may help improve your strength and quality of life, though results are not yet available.

Combining resistance training with progressive whey protein supplementation (up to 60g/day) initiated 3 weeks post-surgery counteracts disproportional fat-free mass loss in patients undergoing metabolic bariatric surgery.

If you have had bariatric surgery, standard care may not be enough to protect your muscle. This protocol suggests starting resistance training (both home and supervised) and gradually increasing whey protein intake to 60g per day, starting 3 weeks after surgery. This combination aims to preserve muscle mass, which is crucial for long-term health and metabolic function.

A multidisciplinary group intervention combining nutritional education, physical activity, and emotional management promotes sustainable weight loss (5-10%) and improves quality of life in adults with obesity.

To manage obesity effectively, consider joining a structured group program that combines nutrition education, physical activity, and emotional support. Look for programs that meet weekly for about two months and include follow-up visits. The social aspect and focus on emotional well-being can help you stick to healthy habits long-term.

Once-weekly subcutaneous semaglutide 2.4 mg produces significant, sustained weight loss (mean 11.80% body weight reduction) and improves cardiometabolic markers in non-diabetic overweight or obese adults compared to placebo.

For non-diabetic adults with obesity, once-weekly 2.4 mg subcutaneous semaglutide is a highly effective intervention for significant weight loss (approx. 12% body weight) and metabolic improvement. While gastrointestinal side effects are common, they are generally manageable and transient.

An intensive weight loss intervention combining total diet replacement (800-850 kcal/day), behavioral support, and weight loss medication achieves and maintains >20% weight loss and improves cardiometabolic risk in adults with severe obesity (BMI ≥35 kg/m²) over 2 years.

For severe obesity, standard 'eat less, move more' advice often fails. This protocol uses a 2-year structured approach: start with a very low-calorie formula diet (800-850 kcal) for 12 weeks with weekly support. If you don't lose enough weight, add a GLP-1 medication. Then, gradually transition to a healthy, low-calorie diet while maintaining exercise. The key is the intensive support and the ability to 'rescue' the plan with formula meals or medication if you regain weight.

Ad libitum consumption of an ultra-processed food (UPF) diet, even when compliant with standard macronutrient dietary guidelines, leads to weight gain and adverse metabolic outcomes, whereas a minimally processed food (MPF) diet leads to weight loss and favorable metabolic changes.

This study protocol investigates whether simply following standard dietary guidelines (like the UK Eatwell Guide) is enough to maintain health if the food is ultra-processed. The hypothesis is that even if you eat the 'right' amounts of fat, sugar, and protein, ultra-processed foods may lead to weight gain, while minimally processed foods lead to weight loss, regardless of macronutrient matching. Until results are published, the implication is that food quality (processing level) matters independently of quantity.